无锡药明生物技术股份有限公司移出“未核实清单”

中国无锡，

2022年10月10日

全球领先的合同研究、开发和生产（CRDMO）公司药明生物（WuXi Biologics, 2269.HK）宣布子公司无锡药明生物技术股份有限公司（WuXi Biologics Co., Ltd.）已于10月7日正式从美国商务部的“未核实清单”（UVL）中移除。

今年2月，药明生物两家子公司——无锡药明生物技术股份有限公司和上海药明生物技术有限公司（WuXi Biologics (Shanghai) Co., Ltd.）由于美国针对部分出口产品用途核实延期而被列入UVL。6月，无锡药明生物技术股份有限公司在中国商务部的协调下成功完成了美国商务部的最终用户访问。

药明生物一直遵守相关法律法规，并致力于以最严格的合规标准运营。公司也正在积极与有关政府部门密切合作，安排另一家子公司上海药明生物技术有限公司的最终用户访问，推动相关UVL移除工作。

- 滑动查看更多介绍 -

Wuxi, China, 

Oct. 10, 2022 

WuXi Biologics ("WuXi Bio", 2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that its subsidiary WuXi Biologics Co., Ltd. located in Wuxi city was removed from the Unverified List (UVL) by the U.S. Department of Commerce, effective October 7, 2022. 

In February 2022, two subsidiaries of WuXi Biologics, namely, WuXi Biologics Co., Ltd. and WuXi Biologics (Shanghai) Co., Ltd., were placed on the UVL due to delayed verifications required for the receipt of certain products exported from the United States. In June, WuXi Biologics Co., Ltd. successfully completed the on-site end-use check conducted by the U.S. Department of Commerce, in coordination with China's Ministry of Commerce (MOFCOM).   

WuXi Biologics has always committed to operating with the highest standard of compliance and in accordance with relevant guidelines and regulations. The company is also working closely with relevant government authorities to schedule the on-site end-use check of its other subsidiary, WuXi Biologics (Shanghai) Co., Ltd., and will commence the UVL delisting process for such entity as soon as the check is completed. 

- Scroll down for more introduction -